Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 15511613

Current and future commitment to hematology research.

Charles M Peterson·Liana Harvath
View original source ↗Export metadata ↓

Abstract

This article provides an overview of the National Heart Lung and Blood Institute's (NHLBI) current and future commitment to hematology research. The paper comprises nine sections: (1) a brief history of how NHLBI incorporated blood research in its mission; (2) a summary of the traditional areas of research interest for blood diseases and resources; (3) a description of how NHLBI has assured and continues to assure a safe blood supply; (4) the current and future plans for transfusion medicine and cellular therapy research; (5) research support for hemoglobinopathies and red cell disorders; (6) research support for thrombosis and hemostatic disorders; (7) current and future research of hematopoietic stem cell biology, and aplastic and preneoplastic conditions; (8) future training for hematologists, and (9) a concluding summary.

Explore related subjects

HematologyHumansNational Institutes of Health (U.S.)ResearchResearch DesignResearch Support as TopicUnited StatesJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Charles M Peterson, Liana Harvath. 2004. Current and future commitment to hematology research.. https://doi.org/10.1016/j.hoc.2004.07.002

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

A tribute to Sidney Farber-- the father of modern chemotherapy.

Sidney Farber, world-renowned paediatric pathologist, made major contributions to his field but is acknowledged as the father of the modern era of chemotherapy. He recognised that folic acid stimulated leukaemic cell growth and enhanced disease progression. He hypothesised that folic acid antagonists would inhibit or arrest the proliferation of cancer cells. His landmark study, published in 1948, demonstrated that a number of folic acid antagonists, including 4-aminopteroyl-glutamic acid (aminopterin) produced temporary remissions in children with acute undifferentiated leukaemia. These observations lead to the development and use of other chemotherapeutic agents, either singly or, more effectively, in combination for treating childhood and adult malignancies. He introduced actinomycin D for the treatment of metastatic and localised Wilms tumour. Under his guidance and leadership, both the 'Jimmy Fund', one of the first comprehensive paediatric oncology treatment centres, and the Children's Cancer Research Foundation, which later became the Dana-Farber Cancer Institute, were founded.

Hematology↗